Attention Laurel Patients:  The new Laurel office is open. The address is 7140 Contee Road, Suite 3500, Laurel, MD 20707….Attention Lanham/Largo Patients: Our new Largo office is now open and our Lanham location is closed permanently. Largo’s address is 9333 Healthcare Way Suite 4100 Largo, MD 20774.

HIPAA Alert:
Potential Data Breach : Learn More

Trial Protocol ID USOR 22322_J3M-MC-JZQB_SUNRAY-01

Trial Description

A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Benjamin Bridges, M.D.

Disease Types

Sponsor

  • ELI LILLY

ClinicalTrials.gov NCT ID

  • NCT06119581